Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrinological problem and is the cause of irregular menstruation in the women of reproductive age. The present study was undertaken to find out novel inflammatory markers in polycystic ovary syndrome (PCOS). Study population was divided into two groups controls (n=100) and cases (n=100) diagnosed with PCOS were recruited for the study. The anthropometric data such as Height, Weight, BMI and, hormonal profile LH, FSH, LH/FSH ratio, Thyroid profile, Testosterone, HOMA-IR, Lipid profile, Monocytes, Neutrophils were noted for all the participants. Taking BMI 25 kg/m as the boundary, the control group was divided into Group A and Group B. Group A includes 53 subjects which is normal BMI group and Group B includes 47 subjects in the High-BMI group and among the cases Group C and Group D. Group C consists of 67 cases (normal BMI group) and 33 cases in the Group D (high BMI group). It is observed that monocyte HDL ratio (M/HDL ratio) and Neutrophil lymphocyte ratio (N/L ratio) in PCOS case group increased significantly (P<0.05) when compared to control group. Through the analysis of differences between the subgroups along with LH, LH/FSH, Total Testosterone, M/HDL ratio, and N/L ratio can be considered as specific indicators of PCOS disease. Through correlation analysis, M/HDL ratio and N/L ratio showed association with hormone levels of LH and Total Testosterone respectively. Through ROC curve, it is found that M/HDL ratio is >10.139 or N/L ratio is >1.7 had diagnostic value for PCOS, and the combined diagnostic value of the two was higher. From the observation of this study, it can be concluded that M/HDL ratio and N/L ratio are not chronic inflammatory indicators caused by obesity but caused by the PCOS disease itself. Therefore, M/HDL ratio and N/L ratio can be used as diagnostic markers for PCOS.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call